Fig. 2: Virtual population responses to TDB and loncastuximab tesirine combinations following 2 cycles of therapy (Day 42). | npj Systems Biology and Applications

Fig. 2: Virtual population responses to TDB and loncastuximab tesirine combinations following 2 cycles of therapy (Day 42).

From: QSP modeling of loncastuximab tesirine with T-cell-dependent bispecific antibodies guides dose-regimen strategy

Fig. 2

Combination indices (CI) were computed 37 to quantify the degree of non-additive effects resulting from the combinations (CI > 1 indicates synergy). (+/−) indicates presence/absence of loncastuximab tesirine. Dashed line: separation between nonresponders and responders. Tumor response classification based on ref. 50. TDB T-cell-dependent bispecific antibody, CI combination index.

Back to article page